These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1242 related articles for article (PubMed ID: 28011478)

  • 1. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
    Liang Y; Chen J; Yu Q; Ji T; Zhang B; Xu J; Dai Y; Xie Y; Lin H; Liang X; Cai X
    Cancer Med; 2017 Dec; 6(12):2787-2795. PubMed ID: 29030911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
    Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
    Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
    Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
    J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
    Honma Y; Harada M
    Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
    Xiao Y; Yan W; Guo L; Meng C; Li B; Neves H; Chen PC; Li L; Huang Y; Kwok HF; Lin Y
    Mol Med Rep; 2017 Feb; 15(2):941-947. PubMed ID: 28035421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
    Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
    Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    D'Alessandro R; Refolo MG; Lippolis C; Giannuzzi G; Carella N; Messa C; Cavallini A; Carr BI
    BMC Cancer; 2014 May; 14():351. PubMed ID: 24885890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib inhibition of hepatic stellate cell proliferation in tumor microenvironment of hepatocellular carcinoma: a study of the sorafenib mechanisms.
    Geng ZM; Jha RK; Li B; Chen C; Li WZ; Zheng JB; Wang L; Huanchen S
    Cell Biochem Biophys; 2014 Jul; 69(3):717-24. PubMed ID: 24633454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.